|Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR ...|
WATERTOWN, Mass., Oct 14, 2014 (BUSINESS WIRE) -- Dicerna Pharmaceuticals, Inc. DRNA, -0.53% a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster ...
MarketWatch - Tue, 14 Oct 2014 14:33
|Alnylam Presents New Clinical and Pre-Clinical Data on RNAi Therapeutics at ...|
DigitalJournal.com - Tue, 14 Oct 2014 05:00
|Alnylam Launches Alnylam Assist™, Dedicated to Providing Support to Patients ...|
... an RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertensive disorders of pregnancy (HDP), including preeclampsia; ALN-GO1, an RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of primary hyperoxaluria ...
DigitalJournal.com - Mon, 20 Oct 2014 05:00
|Alnylam Reveals Positive Data from its Pipeline Candidates|
Initial data from the study is expected next month. Preclinical data on ALN-GO1 being developed for the treatment of primary hyperoxaluria type 1 was also announced. Data revealed efficacy in rodent disease models treated with the candidate. The ...
Zacks.com - Wed, 15 Oct 2014 12:30
|Oxabact® Granted EMA Orphan Drug Designation for Treatment of SBS|
OxThera is currently pursuing a complete clinical development program in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria. Oxabact® previously holds orphan drug designations in the EU and the US for the treatment ...
PR Newswire UK (press release) - Tue, 23 Sep 2014 00:36
|Biochemists solve 'address problem' in cells that leads to lethal kidney disease|
PH1 — short for primary hyperoxaluria 1 — starts at birth and is usually fatal for patients who do not receive both kidney and liver transplants. Approximately half of those with the disease have kidney failure by age 15. Koehler has presented her ...
HealthCanal.com - Fri, 26 Sep 2014 15:52
|UCLA research may lead to new treatments for Parkinson's and Alzheimer's ...|
Examiner.com - Fri, 26 Sep 2014 12:21
|OxThera's Oxabact gets European orphan drug status to treat short bowel ...|
Primary Hyperoxaluria is a rare inborn autosomal genetic disorder leading to markedly elevated levels of endogenous oxalate in plasma and urine. High levels of urinary oxalate cause kidney damage, including recurrent kidney stone formation and/or ...
pharmabiz.com - Tue, 23 Sep 2014 21:30